ASPEN PHAR.UN.ADR /1 O.N. Total Liabilities
ASPEN PHAR.UN.ADR /1 O.N. total liabilities. Based on the latest financial reports, ASPEN PHAR.UN.ADR /1 O.N. (LDZU) has total liabilities worth €46.96 Billion EUR (≈ $54.90 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ASPEN PHAR.UN.ADR /1 O.N. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
Total liabilities of ASPEN PHAR.UN.ADR /1 O.N. from 2022 to 2025. This chart illustrates how ASPEN PHAR.UN.ADR /1 O.N.'s total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of ASPEN PHAR.UN.ADR /1 O.N. to measure how efficiently the company converts operating cash flow to free cash.
ASPEN PHAR.UN.ADR /1 O.N. Competitors by Total Liabilities
The table below lists competitors of ASPEN PHAR.UN.ADR /1 O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jumbo S.A.
AT:BELA
|
Greece | €272.34 Million |
|
BBVA Banco Frances SA ADR
NYSE:BBAR
|
USA | $21.69 Trillion |
|
Beibuwan Port Co Ltd
SHE:000582
|
China | CN¥17.32 Billion |
|
National HealthCare Corporation
NYSE MKT:NHC
|
USA | $427.48 Million |
|
North Copper Shanxi Co Ltd
SHE:000737
|
China | CN¥12.81 Billion |
|
KENON HLDGS LTD
F:76N
|
Germany | €2.20 Billion |
|
Stadler Rail AG
SW:SRAIL
|
Switzerland | CHF5.35 Billion |
|
Agilysys Inc
NASDAQ:AGYS
|
USA | $134.52 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down ASPEN PHAR.UN.ADR /1 O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ASPEN PHAR.UN.ADR /1 O.N. (LDZU) total assets.
Liquidity & Leverage Metrics
ASPEN PHAR.UN.ADR /1 O.N. Total Liabilities Ratios Explained
ASPEN PHAR.UN.ADR /1 O.N. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ASPEN PHAR.UN.ADR /1 O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
The table below shows the annual total liabilities of ASPEN PHAR.UN.ADR /1 O.N. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €51.00 Billion ≈ $59.62 Billion |
-5.91% |
| 2024-06-30 | €54.20 Billion ≈ $63.37 Billion |
+12.81% |
| 2023-06-30 | €48.05 Billion ≈ $56.17 Billion |
+18.83% |
| 2022-06-30 | €40.43 Billion ≈ $47.27 Billion |
-- |
About ASPEN PHAR.UN.ADR /1 O.N.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more